Michael Miller, MD
Family Medicine · Hilliard, OHNPI 1891770665
Payments from drug & device makers
Across 342 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$903
- Novo Nordisk$696
- AstraZeneca$579
- Pfizer$516
- Lilly USA, LLC$466
- Exact Sciences$294
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,884100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 85 | $903 |
| Novo Nordisk | 50 | $696 |
| AstraZeneca | 18 | $579 |
| Pfizer | 33 | $516 |
| Lilly USA, LLC | 30 | $466 |
| Exact Sciences | 12 | $294 |
| Astellas Pharma US Inc | 12 | $249 |
| Tris Pharma Inc | 5 | $235 |
| Abbott | 13 | $230 |
| Phathom Pharmaceuticals, Inc. | 8 | $222 |
| Amgen | 11 | $186 |
| Boehringer Ingelheim | 8 | $154 |
| GSK | 8 | $134 |
| Boston Scientific | 1 | $108 |
| Bayer | 4 | $104 |
| E.r. Squibb & Sons, L.L.C. | 6 | $102 |
| Xeris Pharmaceuticals, Inc. | 5 | $100 |
| Otsuka America Pharmaceutical, Inc. | 6 | $99 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $57 |
| Dexcom, Inc. | 2 | $55 |
| Sanofi Pasteur Inc. | 2 | $50 |
| Cranial Technologies, Inc | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Optinose US, Inc. | 2 | $40 |
| Corcept Therapeutics | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Sanofi | 1 | $18 |
| Novartis | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Noven Therapeutics, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$240
- Dyanavel XR$225
- Quillivant$225
- Quillichew ER$225
- FLUMIST QUADRIVALENT$133
- BREZTRI$133
- FARXIGA$133
- FreeStyle Libre 2$112
- GENERAL PAIN MANAGEMENT$108
How this compares
$5,884 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 60 | $78,425 |
| JardianceEmpagliflozin | 19 | $29,252 |
| OzempicSemaglutide | 25 | $22,851 |
| XareltoRivaroxaban | 13 | $16,404 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 34 | $7,580 |
| Isosorbide Dinitrate | 12 | $1,888 |
| Adacel TdapDiph,pertuss(Acell),tet Vac/Pf | 25 | $1,739 |
| Atorvastatin Calcium | 249 | $1,576 |
| Potassium Chloride | 44 | $1,246 |
| Metoprolol Succinate | 102 | $1,203 |
| Levothyroxine Sodium | 111 | $1,151 |
| Bupropion XlBupropion Hcl | 44 | $1,114 |
| Gabapentin | 57 | $900 |
| SynthroidLevothyroxine Sodium | 34 | $897 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 20 | $792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $516 | $78,42560 claims |
| Boehringer IngelheimJardiance | $154 | $29,25219 claims |
| Novo NordiskOzempic | $696 | $22,85125 claims |
| Johnson & JohnsonXarelto | $14 | $16,40413 claims |
| GSKShingrix | $134 | $7,58034 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $1,151111 claims |
| AbbVieSynthroid | $903 | $89734 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $12 | $35311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Hilliard
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.